Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | PTGES | O14684 | 2/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22271945 | 0.84 | KDM4E (0.41) | ALDH1A1TDP1LMNAKDM4E | |
| SCHEMBL12018164 | 0.82 | POLB (0.41) | ALDH1A1MAPTPOLBSMN1; SMN2TDP1 | |
| SCHEMBL19130728 | 0.81 | POLB (0.41) | ALDH1A1MAPTPOLBSMN1; SMN2TDP1 | |
| SCHEMBL17336270 | 0.79 | PTGES (0.39) | ALDH1A1MAPTPOLBSMN1; SMN2TDP1 | |
| SCHEMBL17002051 | 0.78 | POLB (0.39) | ALDH1A1MAPTPOLBSMN1; SMN2TDP1 | |
| SCHEMBL13840142 | 0.78 | ALDH1A1 (0.44) | ALDH1A1MAPTPOLBSMN1; SMN2TDP1 | |
| SCHEMBL23483021 | 0.77 | ALDH1A1 (0.40) | ALDH1A1MAPTPOLBSMN1; SMN2TDP1 | |
| SCHEMBL19404324 | 0.77 | TDP1 (0.41) | ALDH1A1MAPTPOLBSMN1; SMN2TDP1 | |
| SCHEMBL24455557 | 0.77 | SMN1; SMN2 (0.43) | ALDH1A1MAPTPOLBSMN1; SMN2TDP1 | |
| SCHEMBL12444834 | 0.75 | SMN1; SMN2 (0.34) | ALDH1A1MAPTPOLBSMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4010352-B1 | A METHOD FOR MODIFICATION OF PEPTIDES IMMOBILIZED ON A SOLID SUPPORT BY TRACELESS REDUCTIVELY CLEAVABLE LINKER MOLECULES | GYROS PROTEIN TECH AB (SE) | 2023-10-18 | — | — | EP | disclosed |
| EP-4219446-A2 | TRACELESS REDUCTIVELY CLEAVABLE LINKER MOLECULES FOR PEPTIDE PURIFICATION | Gyros Protein Technologies AB (SE) | 2023-08-02 | — | — | EP | disclosed |
| WO-2021136808-A1 | CONJUGATES UNDERGOING INTRAMOLECULAR REARRANGEMENTS | ASCENDIS PHARMA A/S (DK) | 2021-07-08 | — | — | WO | disclosed |
| US-20210171437-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | VERA THERAPEUTICS INC (US) | 2021-06-10 | — | — | US | disclosed |
| WO-2020043747-A1 | TRACELESS REDUCTIVELY CLEAVABLE LINKER MOLECULES FOR PEPTIDE PURIFICATION | Belyntic GmbH (DE) | 2020-03-05 | — | — | WO | disclosed |
| US-20190055190-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | NEUBASE THERAPEUTICS, INC. | 2019-02-21 | — | — | US | disclosed |
| US-20170276686-A1 | SINGLE MOLECULE PEPTIDE SEQUENCING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2017-09-28 | — | — | US | disclosed |
| US-20170204138-A1 | ANTIBACTERIAL AGENTS | THE UNIVERSITY OF QUEENSLAND (AU) | 2017-07-20 | — | — | US | disclosed |
| US-20160367091-A9 | Personal Care Compositions Comprising a Di-Amido Gellant and Methods of Using | THE PROCTER & GAMBLE COMPANY | 2016-12-22 | — | — | US | disclosed |
| US-20160367091-A9 | Personal Care Compositions Comprising a Di-Amido Gellant and Methods of Using | THE PROCTER & GAMBLE COMPANY | 2016-12-22 | — | — | US | disclosed |
| WO-2011112887-A1 | DI-AMIDO GELLANT FOR USE IN CONSUMER PRODUCT COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2011-09-15 | — | — | WO | disclosed |
| US-20110220536-A1 | Fluid Detergent Compositions Comprising a Di-Amido Gellant, and Processes for Making | THE PROCTER & GAMBLE COMPANY | 2011-09-15 | — | — | US | disclosed |
| WO-2011112886-A1 | FLUID DETERGENT COMPOSITIONS COMPRISING A DI-AMIDO GELLANT, AND PROCESSES FOR MAKING | THE PROCTER & GAMBLE COMPANY (US) | 2011-09-15 | — | — | WO | disclosed |
| US-20110220536-A1 | Fluid Detergent Compositions Comprising a Di-Amido Gellant, and Processes for Making | THE PROCTER & GAMBLE COMPANY | 2011-09-15 | — | — | US | disclosed |
| US-20110224455-A1 | Di-Amido Gellant For Use In Consumer Product Compositions | THE PROCTER & GAMBLE COMPANY | 2011-09-15 | — | — | US | disclosed |
| EP-2365051-A1 | Fluid detergent compositions comprising a di-amido gellant, and process for making | The Procter & Gamble Company (US) | 2011-09-14 | — | — | EP | disclosed |
| EP-2365050-A1 | Di-amido gelaant for use in consumer product compositions | The Procter & Gamble Company (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20100260672-A1 | PEPTIDES THAT SPECIFICALLY BIND HGF RECEPTOR (CMET) AND USES THEREOF | DYAX CORP. (US) | 2010-10-14 | — | — | US | disclosed |
| WO-2007120614-A2 | HOMOGENEOUS ERYTHROPOIETIN AND OTHER PEPTIDES AND PROTEINS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2007-10-25 | — | — | WO | disclosed |
| US-7211240-B2 | Multivalent constructs for therapeutic and diagnostic applications | BRACCO INTERNATIONAL B.V. (NL) | 2007-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190055190-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | TARBP1, TIA1, SSB | ALDH1A1 4569/4885MAPT 2325/4885POLB 421/4885 |
| US-20210171437-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | TARBP1, TIA1, SSB | ALDH1A1 4569/4885MAPT 2325/4885POLB 421/4885 |
| US-20170204138-A1 | ANTIBACTERIAL AGENTS | VNN1, ASNS, AAAS | ALDH1A1 4427/4885MAPT 4603/4885POLB 1399/4885 |
| US-20110224455-A1 | Di-Amido Gellant For Use In Consumer Product Compositions | DAGLA, GNPAT, CDIPT | ALDH1A1 1506/4885MAPT 1057/4885POLB 2941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.